Results 271 to 280 of about 103,862 (301)

The Vasoactivity of PARP Inhibitors

2015
PARP-inhibition has proven to be an attractive therapeutic approach in cancer whereby the effectiveness of DNA-damaging therapy can be enhanced by inhibiting the PARP-mediated DNA-repair process. Generally there is good concordance between enhanced therapeutic efficacy in vitro and that observed in vivo.
Williams, Kaye J., McCrudden, Cian M.
openaire   +2 more sources

PARP inhibitors in ovarian cancer

Seminars in Oncology
Poly-ADP-ribose polymerase inhibitors (PARPis) were first approved for the treatment of epithelial ovarian cancer (EOC), where as a maintenance therapy they transformed clinical management of this disease in both patients with and without homologous recombination deficiency.
Ian S. Goldlust, Elena Guidice, Jung-min Lee   +2 more
openaire   +2 more sources

Understanding and overcoming resistance to PARP inhibitors in cancer therapy

Nature Reviews Clinical Oncology, 2021
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan   +2 more
exaly  

PARP Inhibitors

2014
Joaquin Mateo, Timothy A. Yap, Johann S. De Bono   +2 more
openaire   +1 more source

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

Cancer Cell, 2021
Bin Gui, Tim J Wigle, Yue Ren
exaly  

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

Ca-A Cancer Journal for Clinicians, 2011
Timothy A Yap, Johann Sebastian de Bono
exaly  

PARP inhibitors plough on

Nature Reviews Drug Discovery, 2017
openaire   +2 more sources

PARP Inhibitors

2006
openaire   +1 more source

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

Nature Reviews Molecular Cell Biology, 2017
Arnab Ray Chaudhuri
exaly  

EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition

Cancer Cell, 2020
Sergey Karakashev, Takeshi Fukumoto, Bo Zhao   +2 more
exaly